Juno Therapeutics (JUNO) Misses Q1 EPS by 26c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500, Nasdaq futures rise on tech boost
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Oil rises on Iran war stalemate; near-term potential for further gains seen limited
- L3Harris CEO steps down amid conduct review, shares drop
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
- BOJ eyeing September rate hike, faster pace of tightening, sources say
Juno Therapeutics Reports First Quarter 2016 Financial Results
May 9, 2016 4:10 PM EDT-- Strong cash position of $1.13 billion --
-- 2016 cash burn and operating burn guidance reaffirmed --
-- In April, Celgene exercised opt-in right for the CD19 program --
-- Encouraging early clinical trial data for CD22 and WT-1 --
-- JuMP manufacturing facility operational for JCAR015 Phase II ROCKET trial --
-- Conference call to be held today at 5:00pm Eastern Time --
SEATTLE--(BUSINESS WIRE)-- Juno Therapeutics, Inc. (NASDAQ: JUNO), a... More
